BMS recalls lot of Coumadin on potency risk

Bristol-Myers Squibb is recalling one lot of the blood thinner Coumadin because of potential inconsistencies in potency. The company tested tablets from a returned bottle and found that one tablet was more potent than it should have been. The level of active ingredient in a tablet is obviously key to a blood thinner's effectiveness; too little and the risk of clots increases, but too much and the risk of bleeding grows.

In its announcement, the FDA advised patients with 5-mg tablets to ask their pharmacists whether their prescription was filled from the suspect lot of 1,000-count bottles. If so, they should call their doctors.

As MedPage Today reports, another warfarin product was recalled earlier this year on a dosing problem. Upsher-Smith Laboratories pulled some of its generic warfarin because of the risk that some tablets of varying doses were mixed into the same bottles. One bottle labeled as 3-mg tablets mistakenly contained some 10-mg tablets.

- see the FDA release
- get more from MedPage

Suggested Articles

Novartis is rolling out positive interim phase 3 data on Zolgensma in Europe, which could support the recent launch of the SMA gene therapy there.

The new cost-cutting goal comes on top of a €2.6 billion annual savings target the company already laid out in a revamp initiated in 2018.

As hearings continued on Capitol Hill, a congressional committee said Novartis, Amgen and Mallinckrodt used routine price hikes to meet sales targets.